ANKRD13A

Summary

ANKRD13A (ankyrin repeat domain 13A, HGNC:21268) is a protein-coding gene on chromosome 12q24.11, encoding Ankyrin repeat domain-containing protein 13A (Q8IZ07). Ubiquitin-binding protein that specifically recognizes and binds ‘Lys-63’-linked ubiquitin.

Enables ubiquitin-modified protein reader activity. Involved in negative regulation of protein localization to endosome and negative regulation of receptor internalization. Located in late endosome; perinuclear region of cytoplasm; and plasma membrane.

Source: NCBI Gene 88455 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 79 total
• MANE Select transcript: NM_033121

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21268
Approved symbol	ANKRD13A
Name	ankyrin repeat domain 13A
Location	12q24.11
Locus type	gene with protein product
Status	Approved
Aliases	NY-REN-25
Ensembl gene	ENSG00000076513
Ensembl biotype	protein_coding
OMIM	615123
Entrez	88455

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000261739, ENST00000546476, ENST00000547419, ENST00000547639, ENST00000549826, ENST00000550404, ENST00000551491, ENST00000553025, ENST00000553246, ENST00000553251, ENST00000907288, ENST00000907289, ENST00000907290, ENST00000907291, ENST00000907292, ENST00000907293, ENST00000939845, ENST00000939846, ENST00000939847, ENST00000939848, ENST00000949447, ENST00000949448, ENST00000949449

RefSeq mRNA: 1 — MANE Select: NM_033121 NM_033121

CCDS: CCDS9140

Canonical transcript exons

ENST00000261739 — 15 exons

Exon	Start	End
ENSE00002216022	110024046	110024112
ENSE00002353288	109999430	109999784
ENSE00002363473	110037359	110039763
ENSE00003467475	110036261	110036328
ENSE00003481323	110029478	110029635
ENSE00003482636	110025742	110025823
ENSE00003500653	110027705	110027766
ENSE00003501883	110018345	110018488
ENSE00003504807	110019139	110019328
ENSE00003536566	110016388	110016433
ENSE00003590833	110013125	110013249
ENSE00003615964	110012005	110012137
ENSE00003628799	110030645	110030758
ENSE00003650611	110028512	110028642
ENSE00003680952	110033797	110033957

Expression profiles

Bgee: expression breadth ubiquitous, 261 present calls, max score 98.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.8470 / max 899.3934, expressed in 1821 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
127958	29.6356	1821
127959	0.2114	30

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	98.61	gold quality
amniotic fluid	UBERON:0000173	98.06	gold quality
ileal mucosa	UBERON:0000331	97.89	gold quality
buccal mucosa cell	CL:0002336	97.70	gold quality
adult organism	UBERON:0007023	97.59	gold quality
nasal cavity epithelium	UBERON:0005384	97.53	gold quality
sperm	CL:0000019	97.39	gold quality
blood	UBERON:0000178	97.16	gold quality
upper leg skin	UBERON:0004262	96.88	gold quality
palpebral conjunctiva	UBERON:0001812	96.66	gold quality
oviduct epithelium	UBERON:0004804	96.55	gold quality
penis	UBERON:0000989	96.50	gold quality
parotid gland	UBERON:0001831	96.48	gold quality
calcaneal tendon	UBERON:0003701	96.39	gold quality
skin of hip	UBERON:0001554	96.31	gold quality
trabecular bone tissue	UBERON:0002483	96.10	gold quality
secondary oocyte	CL:0000655	96.08	gold quality
placenta	UBERON:0001987	96.07	gold quality
oral cavity	UBERON:0000167	96.05	gold quality
monocyte	CL:0000576	95.99	gold quality
leukocyte	CL:0000738	95.93	gold quality
tonsil	UBERON:0002372	95.82	gold quality
esophagus squamous epithelium	UBERON:0006920	95.82	gold quality
bone marrow	UBERON:0002371	95.70	gold quality
vermiform appendix	UBERON:0001154	95.63	gold quality
nipple	UBERON:0002030	95.63	gold quality
tendon	UBERON:0000043	95.58	gold quality
bone element	UBERON:0001474	95.48	gold quality
lymph node	UBERON:0000029	95.45	gold quality
stromal cell of endometrium	CL:0002255	95.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

157 targeting ANKRD13A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815

Literature-anchored findings (GeneRIF, showing 6)

• overexpression of wild-type as well as truncated-mutant Ankrd 13A, 13B and 13D proteins strongly inhibited rapid endocytosis of ubiquitinated EGFR from the surface in EGF-treated cells (PMID:22298428)
• the microRNA miR-204 promotes both mesenchymal neural crest and lens cell migration and elongation by the direct targeting of the Ankrd13A gene. (PMID:23620728)
• We validated ANKRD13A as a novel constituent of BCR signalosome and showed that BCR-induced phosphorylation of RAB7A at S72 regulates its association with its effector proteins and with endo-lysosomal compartments. (PMID:26038114)
• The Ankrd13 family of ubiquitin-interacting motif (UIM)-containing proteins are novel VCP-interacting molecules in the endosome. (PMID:26797118)
• LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A. (PMID:34694569)
• ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-kappaB. (PMID:34839354)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ankrd13a	ENSDARG00000061901
mus_musculus	Ankrd13a	ENSMUSG00000041870
rattus_norvegicus	Ankrd13a	ENSRNOG00000001204
drosophila_melanogaster	CG15118	FBGN0034418
caenorhabditis_elegans		WBGENE00015978

Paralogs (3): ANKRD13C (ENSG00000118454), ANKRD13D (ENSG00000172932), ANKRD13B (ENSG00000198720)

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 13A — Q8IZ07 (reviewed: Q8IZ07)

Alternative names: Protein KE03

All UniProt accessions (6): Q8IZ07, F8W150, H0YIN8, Q3ZTS7, S4R3D2, S4R3U2

UniProt curated annotations — full annotation on UniProt →

Function. Ubiquitin-binding protein that specifically recognizes and binds ‘Lys-63’-linked ubiquitin. Does not bind ‘Lys-48’-linked ubiquitin. Positively regulates the internalization of ligand-activated EGFR by binding to the Ub moiety of ubiquitinated EGFR at the cell membrane.

Subunit / interactions. Interacts (via the UIM 3 and 4 repeats) with EGFR (ubiquitinated); the interaction is direct, inhibited by ANKRD13A monoubiquitination and may regulate EGFR internalization.

Subcellular location. Cell membrane. Late endosome.

Post-translational modifications. Monoubiquitinated, inhibits interaction with ubiquitinated EGFR.

Domain organisation. The UIM repeats 3 and 4 are required for binding to ubiquitinated EGFR and ‘Lys-63’-linked ubiquitin.

RefSeq proteins (1): NP_149112* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR003903	UIM_dom	Conserved_site
IPR021832	ANKRD13	Family
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR055285	ANKRD13_C	Domain

Pfam: PF11904, PF12796

UniProt features (16 total): mutagenesis site 4, domain 4, repeat 2, sequence conflict 2, modified residue 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZ07-F1	74.08	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 205, 586

Mutagenesis-validated functional residues (4):

Position	Phenotype
491–495	no effect on ’lys-63’-linked ubiquitin binding and interaction with egfr. no effect on ’lys-63’-linked ubiquitin binding
527–531	no effect on ’lys-63’-linked ubiquitin binding and interaction with egfr. no effect on ’lys-63’-linked ubiquitin binding
557–561	slightly inhibits ’lys-63’-linked ubiquitin binding and strongly inhibits interaction with egfr. no effect on ’lys-63’-l
582–586	abolishes ’lys-63’-linked ubiquitin binding and strongly inhibits interaction with egfr. abolishes ’lys-63’-linked ubiqu

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 198 (showing top): MODULE_255, MODULE_317, GOBP_NEGATIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_REGULATION_OF_RECEPTOR_INTERNALIZATION, GOBP_REGULATION_OF_RECEPTOR_MEDIATED_ENDOCYTOSIS, TGIF_01, ZIC1_01, GOBP_RECEPTOR_INTERNALIZATION

GO Biological Process (2): negative regulation of receptor internalization (GO:0002091), negative regulation of protein localization to endosome (GO:1905667)

GO Molecular Function (2): ubiquitin-modified protein reader activity (GO:0140036), protein binding (GO:0005515)

GO Cellular Component (7): cytoplasm (GO:0005737), late endosome (GO:0005770), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), endosome (GO:0005768), endomembrane system (GO:0012505), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of receptor internalization	1
receptor internalization	1
negative regulation of receptor-mediated endocytosis	1
protein localization to endosome	1
negative regulation of protein localization	1
regulation of protein localization to endosome	1
ubiquitin-like protein reader activity	1
binding	1
intracellular anatomical structure	1
endosome	1
membrane	1
cell periphery	1
cytoplasm	1
endomembrane system	1
cytoplasmic vesicle	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

790 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD13A	C12orf43	Q96C57	532
ANKRD13A	VCP	P55072	513
ANKRD13A	UBASH3A	P57075	477
ANKRD13A	GPHA2	Q96T91	433
ANKRD13A	UBXN6	Q9BZV1	383
ANKRD13A	MMAB	Q96EY8	376
ANKRD13A	ENKD1	Q9H0I2	366
ANKRD13A	TTC39C	Q8N584	352
ANKRD13A	PPP2R5B	Q15173	349
ANKRD13A	UBASH3B	Q8TF42	346
ANKRD13A	C2orf69	Q8N8R5	342
ANKRD13A	G3V325	G3V325	336
ANKRD13A	TMEM25	Q86YD3	336
ANKRD13A	GLTP	Q9NZD2	333
ANKRD13A	SMIM14	Q96QK8	332

IntAct

156 interactions, top by confidence:

A	B	Type	Score
ENTREP1	WWP2	psi-mi:“MI:0914”(association)	0.850
TSPAN5	ADAM10	psi-mi:“MI:0914”(association)	0.800
ARRDC3	WWP2	psi-mi:“MI:0914”(association)	0.770
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CSNK1G3	CSNK1G2	psi-mi:“MI:0914”(association)	0.640
GNAI3	RGS12	psi-mi:“MI:0914”(association)	0.640
CFTR	HAX1	psi-mi:“MI:0914”(association)	0.610
MS4A10	NEDD4	psi-mi:“MI:0914”(association)	0.590
ASB7	POLR3A	psi-mi:“MI:0914”(association)	0.530
ZDHHC11	APOB	psi-mi:“MI:0914”(association)	0.530
RALB	DBT	psi-mi:“MI:0914”(association)	0.530
ARRDC4	WWP2	psi-mi:“MI:0914”(association)	0.530
LDLRAD4	WWP2	psi-mi:“MI:0914”(association)	0.530
IZUMO1	ADCY3	psi-mi:“MI:0914”(association)	0.530
ZNRF1	NMT2	psi-mi:“MI:0914”(association)	0.530
PI4K2A	GABARAP	psi-mi:“MI:0914”(association)	0.530
ENTREP3	NEDD4	psi-mi:“MI:0914”(association)	0.530
SLC39A4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
TMEM31	PSMD11	psi-mi:“MI:0914”(association)	0.530
CCR6	PODXL	psi-mi:“MI:0914”(association)	0.530
SCAMP2	SCAMP3	psi-mi:“MI:0914”(association)	0.530
DLK1	SCAMP3	psi-mi:“MI:0914”(association)	0.530

BioGRID (201): ANKRD13A (Two-hybrid), UBC (Reconstituted Complex), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ANKRD13A (Co-fractionation), ANKRD13A (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8FDW4, A4QP73, A4UMC5, B4NYQ2, B5X0I6, C4R2L0, D4A6D7, O09012, O70525, O74711, P33292, P50542, Q01495, Q1RMV0, Q29RR5, Q2M2R8, Q2TXF0, Q54MD1, Q5AV00, Q5F259, Q5R4F4, Q5U2Y6, Q5ZMQ9, Q6BM14, Q6CT48, Q6DI35, Q6DKK2, Q6FM42, Q6K687, Q6PD24, Q6ZTN6, Q752X0, Q80UP5, Q86YJ7, Q8C437, Q8CC21, Q8IYB4, Q8IZ07, Q8L611, Q920N5

Diamond homologs: A4II29, Q28C34, Q3UX43, Q5F259, Q5U5A6, Q6NRD0, Q6PD24, Q6ZTN6, Q7T3Y0, Q7Z6K4, Q7ZUV0, Q7ZYD9, Q80UP5, Q86WC6, Q86YJ7, Q8IZ07, Q8N6S4, Q91ZA8, Q9D119, Q9TXQ1, Q3V096, P42570, Q0VC93, Q28FJ2, Q4JHE0, Q569N2, Q7Z713

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SMURF1	unknown	ANKRD13A	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 202 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Amino acid transport across the plasma membrane	5	11.5×	8e-03
R-HSA-425366	7	9.7×	2e-03
SLC-mediated transmembrane transport	15	6.8×	4e-06
Transport of small molecules	20	3.8×	7e-05
Neutrophil degranulation	18	3.2×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
post-Golgi vesicle-mediated transport	5	29.6×	6e-04
amino acid transport	6	10.5×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2586 predictions. Top by Δscore:

Variant	Effect	Δscore
12:109999782:CAGG:C	donor_loss	1.0000
12:109999783:AGGT:A	donor_loss	1.0000
12:109999784:GGTG:G	donor_loss	1.0000
12:109999785:GT:G	donor_loss	1.0000
12:109999786:T:A	donor_loss	1.0000
12:110012003:A:AG	acceptor_gain	1.0000
12:110012003:A:AT	acceptor_loss	1.0000
12:110012004:G:GT	acceptor_gain	1.0000
12:110012004:G:T	acceptor_loss	1.0000
12:110012004:GA:G	acceptor_gain	1.0000
12:110012004:GAAT:G	acceptor_gain	1.0000
12:110012133:GACAG:G	donor_gain	1.0000
12:110012134:ACAG:A	donor_gain	1.0000
12:110012135:CAG:C	donor_gain	1.0000
12:110012135:CAGGT:C	donor_loss	1.0000
12:110012136:AG:A	donor_gain	1.0000
12:110012137:GG:G	donor_gain	1.0000
12:110012138:G:GG	donor_gain	1.0000
12:110013121:CTA:C	acceptor_loss	1.0000
12:110013122:TA:T	acceptor_loss	1.0000
12:110013123:A:AG	acceptor_gain	1.0000
12:110013123:AG:A	acceptor_loss	1.0000
12:110013124:G:GA	acceptor_gain	1.0000
12:110013124:GTT:G	acceptor_gain	1.0000
12:110013124:GTTTT:G	acceptor_gain	1.0000
12:110013217:G:GT	donor_gain	1.0000
12:110019131:A:AG	acceptor_gain	1.0000
12:110019134:A:AG	acceptor_gain	1.0000
12:110019136:TAG:T	acceptor_loss	1.0000
12:110019137:A:AG	acceptor_gain	1.0000

AlphaMissense

3914 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:110012131:T:A	W75R	1.000
12:110012131:T:C	W75R	1.000
12:110013136:G:C	A81P	1.000
12:110016415:T:A	W128R	1.000
12:110016415:T:C	W128R	1.000
12:110025781:C:A	R281S	1.000
12:110025782:G:C	R281P	1.000
12:110025794:T:C	L285P	1.000
12:110012048:T:C	L47P	0.999
12:110013137:C:A	A81D	0.999
12:110016421:T:C	F130L	0.999
12:110016422:T:C	F130S	0.999
12:110016423:C:A	F130L	0.999
12:110016423:C:G	F130L	0.999
12:110016427:A:C	S132R	0.999
12:110016429:C:A	S132R	0.999
12:110016429:C:G	S132R	0.999
12:110016430:T:A	W133R	0.999
12:110016430:T:C	W133R	0.999
12:110018392:A:G	K150E	0.999
12:110018394:A:C	K150N	0.999
12:110018394:A:T	K150N	0.999
12:110018408:T:C	L155P	0.999
12:110018410:C:A	R156S	0.999
12:110018411:G:C	R156P	0.999
12:110018467:A:C	S175R	0.999
12:110018469:T:A	S175R	0.999
12:110018469:T:G	S175R	0.999
12:110025781:C:G	R281G	0.999
12:110028569:T:C	Y335H	0.999

dbSNP variants (sampled 300 via entrez): RS1000103581 (12:110009129 T>C), RS1000136168 (12:110008863 C>A,T), RS1000198569 (12:110015291 C>T), RS1000324268 (12:110008909 ATT>A,AT,ATTT), RS1000424766 (12:110008633 C>G), RS1000661736 (12:110007379 T>C), RS1000712311 (12:110007067 C>T), RS1000830052 (12:110037365 C>G), RS1000908268 (12:110003834 C>A), RS1000987362 (12:110013808 T>C), RS1001038671 (12:110030817 G>A), RS1001050760 (12:110022895 T>C), RS1001178337 (12:110029982 C>T), RS1001251619 (12:110029072 T>A), RS1001356161 (12:110014499 T>C)

Disease associations

OMIM: gene MIM:615123 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001822_15	Metabolite levels (MHPG)	4.000000e-07
GCST007267_131	Systolic blood pressure	3.000000e-08
GCST008103_145	Bipolar disorder	3.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005133	MHPG measurement
EFO:0006335	systolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects cotreatment, increases methylation	4
sodium arsenite	increases expression, decreases expression, affects cotreatment, increases abundance	2
Valproic Acid	affects expression, increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
trichostatin A	affects expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Acetaminophen	increases expression	1
Arsenic	increases expression, affects cotreatment, increases abundance	1
Atrazine	decreases expression	1
Caffeine	decreases phosphorylation	1
Dexamethasone	affects cotreatment, increases expression, decreases expression	1
Indomethacin	affects cotreatment, increases expression, decreases expression	1
Lead	affects expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Methyl Methanesulfonate	increases expression	1
Phthalic Acids	affects methylation	1
Tretinoin	increases expression	1
Urethane	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression, decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1JI	Abcam HeLa ANKRD13A KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.